Work

Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose dexamethasone in multiple myeloma (MM).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.e19517

Authors: Natalie Scott Callander, Susanna J. Jacobus, Matthias Weiss, Shaji Kumar, Rafael Fonseca, David Samuel DiCapua Siegel, Michael S. Katz, Rafat Abonour, Michael E. Williams, Philip R. Greipp, Vincent Rajkumar, Eastern Cooperative Oncology Group

Institutions: University of Wisconsin–Madison, Dana-Farber Cancer Institute, Mayo Clinic, Mayo Clinic in Arizona, Hackensack University Medical Center, International Myeloma Foundation, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia Medical Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2249404521

Cites:

Cited by: 1

Related to: 10